Moderna fell 3% as Morgan Stanley raised its target but kept a neutral rating while awaiting more cancer-trial evidence.
Why Moderna Stock Is Falling Today
Moderna fell 3% after Morgan Stanley, an investment bank, kept a neutral rating despite raising its price target. Shares last traded at $209.85 in trading after the market closed, compared with the prior close of $215.27. The improved outlook for its cancer treatment did not translate into a stronger stock recommendation.
Moderna Intismeran Melanoma Trial Results
Moderna’s experimental cancer treatment Intismeran is tailored to markers in each patient’s tumor to help the immune system recognize cancer. Its melanoma study tested treatment after surgery to reduce the chance of this serious skin cancer returning. Morgan Stanley said the findings showed the approach works in a late-stage trial, the final major test before regulators consider approval.
Moderna Morgan Stanley Price Target Increase
Morgan Stanley raised its price target to $200 from $95, leaving it below the latest share price. It kept Equalweight, a neutral recommendation compared with the stocks it tracks, while awaiting kidney-cancer evidence. The higher target comes after Moderna’s earlier melanoma presentation and reflects a larger estimated sales opportunity.
Moderna Opening Bounce Meets Sellers
The opening change was +2.13%, and shares reached a high near $220 this morning before sellers met the bounce. Moderna had a daily move this large as recently as the prior session, so today’s swing is not unusually large for this stock.
Quick Financial Overview
Moderna is a large-cap, a business valued at $84.91B, with real sales and a quarterly profit. It held $5.17B in cash, cash equivalents, and short-term investments as of September 30, 2026. That would cover about ten months if its latest quarterly rate of cash use continued.
Moderna Revenue and Cash Use
Quarterly revenue was $1.31B, with net income of $162.0M. Yet operations used $1.56B in cash during the same period. Reported profit and cash flow measure different things, so earnings alone do not show how much money remains to fund development.
Moderna Stock Pullback Interrupts Its Longer Rally
Moderna has retreated from the $250 level over the past five sessions, interrupting a longer rally that left shares up 352% over six months. Today’s failed bounce shows that buyers have not yet reversed the recent selling.
Trading Perspective
Reclaiming the $220 level, the bottom of today’s opening gap, would be a recovery test because shares already trade below it. Beyond that, the $280 level remains the longer-term ceiling where buyers previously ran out of strength. A bounce that stalls below the gap would leave the recent decline intact.
Moderna Kidney Cancer Trial Next Step
The kidney-cancer study is a mid-stage trial, which tests whether treatment works while continuing to assess safety. Its next checkpoint is an interim analysis, a planned look at results before the study ends.
Conclusion
Morgan Stanley expects the early kidney-cancer results late this year or early next year. Success would support use beyond melanoma; a weak result would limit that case without undoing the skin-cancer findings. The existing cash cushion supports the wait if spending continues at the recent rate.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:







Leave a reply